Efficacy News and Research

RSS

High doses of fish oil supplements do not reduce atrial fibrillation

High doses of fish oil supplements, rich in omega-3 fatty acids, do not reduce atrial fibrillation, a common type of irregular heartbeat in which the heart can beat as fast as 150 beats a minute. The results of the AFFORD trial led by the Montreal Heart Institute were published in the Journal of the American College of Cardiology on October 7th.

14 Oct 2014

LaVision BioTec report on users of light sheet microscopy in the Miami Project to Cure Paralysis

LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on users of their Ultramicroscope Light Sheet Fluorescence Microscope system to aid the research of the Miami Project to Cure Paralysis under the supervision of Professor Vance Lemmon, the Walter G. Ross Distinguished Chair in Developmental Neuroscience & Professor of Neurological Surgery at the University of Miami.

14 Oct 2014

Scientists evaluate efficacy of non-synthetic bed bug pesticides

Concerns over human-insecticide exposure has stimulated the development of alternative bed bug control materials, and many essential oil-based pesticides and detergent insecticides have been developed in recent years.

13 Oct 2014

Study shows diphenhydramine suppresses cough reflex sensitivity with Dr. Cocoa formulation

Cough is among the most common complaints for which patients seek medical attention. Leading cough researcher Peter V. Dicpinigaitis, M.D., Professor of Clinical Medicine at New York's Albert Einstein College of Medicine, recently conducted a new cough challenge study among adults, whose results were first presented at the European Respiratory Society International Congress in September 2014.

13 Oct 2014

New surface coating for medical devices prevents blood from clotting

From joint replacements to cardiac implants and dialysis machines, medical devices enhance or save lives on a daily basis. However, any device implanted in the body or in contact with flowing blood faces two critical challenges that can threaten the life of the patient the device is meant to help: blood clotting and bacterial infection.

13 Oct 2014

Grand Challenges Canada announces 11 seed grants to improve mental health in developing countries

On the day the world is collectively raising awareness on mental health issues, Grand Challenges Canada, funded by the Government of Canada, announced new funding for 11 novel ideas to improve mental health in developing countries, one of the biggest unmet needs of our time. Seed grants of up to $270,000 are awarded to 11 innovators from Canada and low- and middle-income countries, totalling $2.9 million CAD.

10 Oct 2014

Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMN Rx in infants and children with spinal muscular atrophy at the 19th International World Muscle Society (WMS) Congress in Berlin, Germany.

10 Oct 2014

Economic cost of adolescent chronic pain is $19.5 billion a year

Research in The Journal of Pain estimated that the economic cost of moderate to severe chronic pain in adolescents is $19.5 billion a year. The Journal of Pain is the peer-reviewed publication of the American Pain Society.

10 Oct 2014

Study addresses the challenge of genomic heterogeneity

Known cancer-driving genomic aberrations in localized lung cancer appear to be so consistently present across tumors that a single biopsy of one region of the tumor is likely to identify most of them, according to a paper published today in Science.

10 Oct 2014

InSightec to share new insights at FUS symposium

InSightec, world leader in MR-guided Focused Ultrasound (MRgFUS) will be on site at the Focused Ultrasound International Symposium (FUS) to share key insights gained in the past two years of using its non-invasive MRgFUS solution for treating a variety of neurosurgical, oncological and gynecological indications.

9 Oct 2014

VolitionRx announces additional colorectal cancer data at International Conference of Anticancer Research

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests, today announced that further data analysis from its colorectal cancer study was presented today at the 9th International Conference of Anticancer Research, being held October 6-10, 2014 in Sithonia, Greece.

9 Oct 2014

RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

Rebiotix Inc. announced today that results of the Phase 2 PUNCH CD Study found that the overall efficacy of RBX2660 in the treatment of recurrent Clostridium difficile infection was 87.1%. The study also found that administration of RBX2660 was well-tolerated and demonstrated satisfactory safety in the 60-day interim analysis.

9 Oct 2014

HemoShear completes first-phase development of novel cancer drug discovery platform

HemoShear today announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations.

9 Oct 2014

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.

9 Oct 2014

Higher doses of neuroleptics needed for pregnant women with psychiatric conditions

The new generation of neuroleptics for psychiatric conditions has the advantage over older medications of fewer adverse side effects. An investigation into their effectiveness in pregnant women has now discovered that higher doses are needed during pregnancy to maintain the desired effect.

9 Oct 2014

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Astellas reported today that isavuconazole demonstrated successful outcomes in the treatment of mucormycosis according to data from the phase 3 isavuconazole VITAL study being presented at IDWeek on October 10, 2014, in Philadelphia, Pa.

8 Oct 2014

Ruthigen begins Phase 1/2 clinical trial of RUT58-60

Ruthigen Inc., a biopharmaceutical company focused on pioneering new therapies to improve patient outcomes and reduce healthcare costs associated with infections related to post-operative invasive procedures, announces the initiation of a Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.

8 Oct 2014

Combination of behavioral support and medication helps people stop smoking

Numerous randomized clinical trials have shown the effectiveness of the two major forms of smoking cessation treatment - behavioral support and medication - in helping smokers quit. Researchers have now demonstrated that this approach can successfully translate to the "real world" and that a combination of the two treatments offers almost a threefold chance of success over attempts to quit without using a cessation aid.

8 Oct 2014

Research finding could potentially lead to new strategies to improve cancer therapies

Cells are generally able to repair spontaneous damage that arises in their genetic material. Unfortunately, the DNA repair process is not perfect and sometimes, damaged DNA gets passed on to newly made cells. A team of researchers at the Center for Molecular Biology of Heidelberg University has recently discovered that in yeast cells, the amount of nutrients that cells are exposed to can affect DNA surveillance and repair mechanisms and therefore the quality of their DNA.

8 Oct 2014

New partners join Grand Challenges Canada to help protect early brain development

Grand Challenges Canada, funded by the Government of Canada, today welcomed three new partners to the Saving Brains Grand Challenge: Aga Khan Foundation Canada, Norlien Foundation and World Vision Canada. These organizations strengthen the existing partnership with the Bernard van Leer Foundation, the Bill & Melinda Gates Foundation, and the Maria Cecilia Souto Vidigal Foundation.

8 Oct 2014

Efficacy News and Research

High doses of fish oil supplements do not reduce atrial fibrillation

LaVision BioTec report on users of light sheet microscopy in the Miami Project to Cure Paralysis

Scientists evaluate efficacy of non-synthetic bed bug pesticides

Study shows diphenhydramine suppresses cough reflex sensitivity with Dr. Cocoa formulation

New surface coating for medical devices prevents blood from clotting

Grand Challenges Canada announces 11 seed grants to improve mental health in developing countries

Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

Economic cost of adolescent chronic pain is $19.5 billion a year

Study addresses the challenge of genomic heterogeneity

InSightec to share new insights at FUS symposium

VolitionRx announces additional colorectal cancer data at International Conference of Anticancer Research

RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

HemoShear completes first-phase development of novel cancer drug discovery platform

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

Higher doses of neuroleptics needed for pregnant women with psychiatric conditions

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Ruthigen begins Phase 1/2 clinical trial of RUT58-60

Combination of behavioral support and medication helps people stop smoking

Research finding could potentially lead to new strategies to improve cancer therapies

New partners join Grand Challenges Canada to help protect early brain development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News